Adrenaline

NEW YORK, Aug. 20, 2024 /PRNewswire/ -- Platelets are circulating cell fragments known to clump up and form blood clots that stop bleeding in injured vessels. Cardiologists have long known that platelets can become "hyperreactive" to cause abnormal clotting that blocks arteries and contributes to heart attack, stroke, and poor blood flow (peripheral artery disease) in the legs of millions of Americans. Despite this major contribution to cardiovascular risk, routine measurement of whether each patient's platelets clump (aggregate) too much has been infeasible to date. This is because results delivered by the method typically used to determine platelet activity, called platelet aggregometry, vary too much from lab to lab. To address this challenge, a new study, led by researchers at NYU Grossman School of Medicine, precisely identified a group of patients with platelet hyperreactivity, and then surveyed them to reveal 451 genes the activity of which differed significantly in those with hyperreactive platelets versus those without. Publishing online August 20 in Nature Communications, the research team then used bioinformatics to assign a weight to each genetic difference and generate each patient's Platelet Reactivity ExpresSion Score (PRESS). "Our results demonstrate that our new platelet-centric scoring system can, for the first time and across populations, circumvent aggregometry to reliably predict platelet hyperreactivity and the related risk of cardiovascular events," said corresponding study author Jeffrey Berger, MD, director of the Center for the Prevention of Cardiovascular Disease at NYU Grossman School of Medicine. The researchers found that their new score can detect platelet hyperreactivity, both in patients at imminent risk of heart attack, and in healthy patients whose future risk may otherwise remain unknown. "Physicians currently prescribe aspirin, a medication that counters platelet activity, to patients based on available risk factors, including high cholesterol or high blood pressure, which are not directly related to platelet function," added Berger. "PRESS promises to help physicians confine anti-platelet treatment to the people most likely to benefit: those with platelet hyperreactivity." By acting on platelets, aspirin is known to protect against abnormal clotting, but in doing so, increases risk of bleeding, said the study authors. The field needs a reliable way to identify patients for whom protection against heart attack outweighs bleeding risk. Platelet Score Progress toward the design of the PRESS began with a shift in the field away from aggregometry methods that expose each patient's platelets to high doses of proteins known to strongly encourage aggregation. Platelets that do not aggregate under these extreme conditions are labelled dysfunctional, but these tests were not designed to directly assess hyperreactivity. Experience on Berger's team and in other labs working with platelets led to a switch to an aggregometry method that instead exposes platelets to a very small dose (4 μM or microMolar) of epinephrine known to weakly encourage aggregation. The field settled on 60 percent aggregation in platelet sample at 0.4 μM of epinephrine as the threshold over which platelets would be designated as hyperreactive. While this method is not new, the current study provided new evidence that patients meeting this hyperreactivity definition are at much greater risk for cardiovascular events. Specifically, the team used the newer, but still labor-intensive, aggregometry method to track the impact of platelet activity status on MACLE (major adverse cardiovascular and limb events), a composite measure of death, heart attack, stroke, and lower extremity amputations in patients enrolled in the Platelet Activity and Cardiovascular Events in PAD (PACE-PAD) clinical study. MACLE was measured in this group of high-risk patients after they underwent lower extremity revascularization (LER), a group of procedures that open blocked arteries. In 254 PACE-PAD patients whose platelet aggregation was measured with 0.4 μM of epinephrine, 17.5% showed hyperreactive platelets, and those patients with hyperreactivity had more than double the incidence of heart attack, stroke, or acute limb ischemia or major amputation within the 30 days after LER than those without hyperreactivity. While the team has an uncommon expertise in aggregometry, and despite these learnings, their goal was to create a generalizable measure of risk that could one day be easily performed in physicians' offices. To make global implementation feasible, the researchers designed PRESS based on a genetic signature and independent of blood collection techniques and other variables that affect aggregometry. To create PRESS, the researchers collected platelet genetic material from 129 PACE-PAD patients before their LER procedure and designed the score based on the genetic differences seen with hyperreactivity. The researchers confirmed the score's accuracy by checking it against platelet aggregation tests. To further validate PRESS, the team explored the link between the score and cardiovascular risk in several other patient groups. Among these was the Heart Attack Research Program, which enrolled women undergoing coronary angiography. In this group PRESS was found to be higher in those who had a heart attack than in those with stable coronary artery disease. Among patients with lower extremity atherosclerosis followed for an average of 18 months, patients with PRESS above the middle (average) score were 90% percent more likely to have a major cardiovascular event than those below it. "In current practice, anti-platelet therapy is not routinely recommended for the prevention of a first heart attack or stroke, but a platelet-based test would help to identify patients at highest risk, and those who would benefit most from anti-platelet therapy to prevent a cardiovascular event," says study author Tessa Barrett, PhD, assistant professor in the departments of Medicine and Pathology at NYU Langone. "Our score has the potential to further personalize cardiovascular disease risk prevention." Along with Berger and Barrett, study authors from the Department of Medicine at NYU Grossman School of Medicine were Macintosh Cornwell, Yuhe Xia, Matthew Muller, Nathaniel Smilowitz, Jonathan Newman, Florencia Schlamp, Caron Rockman, Kelly Ruggles, and, Judith Hochman, MD , associate director of the Leon H Charney Division of Cardiology. Also, a study author was Deepak Voora, MD, of the Duke Center for Applied Genomics & Precision Medicine. Support for this study was provided by the National Institutes of Health (NIH) grants R01HL114978, R35HL144993, R01HL167917, 5R01HL118049, and K23HL150315. The NYU CTSA grant UL1TR001445 from the National Center for Advancing Translational Sciences (NCATS) partly supported the study. The NYU Langone Health DART Genomic Technology Core is partially funded by NYU Cancer Center Support Grant NIH/NCI P30CA016087. Contact: Gregory Williams, [email protected] SOURCE NYU Langone Health System

DUBLIN--( BUSINESS WIRE )--The "Autoinjectors - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Autoinjectors is estimated at US$59.7 Billion in 2023 and is projected to reach US$168.2 Billion by 2030, growing at a CAGR of 13.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The Rheumatoid Arthritis segment is expected to experience significant growth, reaching US$47.6 billion by 2030 with a CAGR of 13.8%. Similarly, the Anaphylaxis segment is projected to grow at a 13.6% CAGR over the next eight years. The U.S. market is estimated at $16.1 billion in 2023, while China is forecasted to grow at an impressive 18.4% CAGR, reaching $40.4 billion by 2030. Other key regions, including Japan, Canada, Germany, and the Asia-Pacific, are also highlighted for their growth trends. The report provides comprehensive market data, including independent analysis of annual sales and market forecasts in US$ million from 2023 to 2030. It offers in-depth regional analysis with detailed insights into key markets such as the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. The report also includes profiles of major companies like AbbVie, Inc., Amgen, Inc., and Antares Pharma, Inc., among others. This report is valuable for those seeking a detailed market analysis of the Global Autoinjectors Market, covering all major geographic regions and market segments. It provides competitive insights into the market presence of major players across different geographies, as well as future trends and drivers shaping the industry's future. Additionally, the report offers actionable insights to help identify new revenue opportunities and support strategic business decisions, with complimentary updates provided for one year to keep readers informed of the latest market developments. Key Questions Answered: How is the Global Autoinjectors Market expected to evolve by 2030? What are the main drivers and restraints affecting the market? Which market segments will grow the most over the forecast period? How will market shares for different regions and segments change by 2030? Who are the leading players in the market, and what are their prospects? Key Attributes: Report Attribute Details No. of Pages 194 Forecast Period 2023 - 2030 Estimated Market Value (USD) in 2023 $59.7 Billion Forecasted Market Value (USD) by 2030 $168.2 Billion Compound Annual Growth Rate 13.8% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Rapid Shift from Self-Injectors to Autoinjectors for Easy and Safe Administration of Drugs Drives Demand North America: The Largest Market for Autoinjectors Autoinjectors - Global Key Competitors Percentage Market Share in 2022 (E) Global Epinephrine Autoinjector market: Percentage Breakdown of Volume Sales by Leading Players for the Year 2019E Global Economic Update Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) MARKET TRENDS & DRIVERS Rising Prevalence of Targeted Therapies such as Cancer, Rheumatoid Arthritis, Multiple Sclerosis and Diabetes: A Strong Growth Driver Number of New Cases of Cancer Worldwide for the Years 2012, 2015, 2020, 2025 and 2030 Diabetes Prevalence in the Age-Group of 20-79 Years in Millions by Region for the Years 2018, 2021 and 2025 Global Injectable Drug Delivery Market: Revenues in US$ Billion for the Years 2016, 2018, 2020, 2022 and 2024 Rising Incidence of Anaphylaxis and Increased Prescription Rate of Epinephrine Autoinjectors Boosts Market Demand Increasing Number of Regulatory Approvals for Autoinjectors in Various Diseases Generic Autoinjectors Take Center Stage Patent Expiry of Biologics to Drive the Demand for Biosimilars Strong Government Support and Favorable Reimbursement Policies Propel Market Growth Challenges Development of Autoinjectors for Multiple Drug Viscosities: A Major Challenge Increasing Demand for Alternative Drug Delivery Modes Hampers Market Growth Emergence of Oral Diabetic Agents, Oral Insulin and Epinephrine Nasal Sprays Poses Huge Challenge for Autoinjectors Market Product Overview Autoinjector: Definition FOCUS ON SELECT PLAYERS (Total 42 Featured): AbbVie, Inc. Amgen, Inc. Antares Pharma, Inc. Becton, Dickinson and Company Consort Medical PLC Eli Lilly and Company Haselmeier GmbH Mylan NV Owen Mumford Ltd. SHL Group Teva Pharmaceutical Industries Ltd. Ypsomed AG For more information about this report visit https://www.researchandmarkets.com/r/k75m68 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.